Vascular interactions between endogenous prostanoids and vasoactive peptide mediators in gastric damage.
Whittle
B J
BJ
Department of Pharmacology, Wellcome Research Laboratories, Beckenham, Kent., U.K.
Esplugues
J V
JV
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D000818:Animals; D002211:Capsaicin / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors; D016232:Endothelins / Q000494:pharmacology; D005753:Gastric Mucosa / Q000098:blood supply* / Q000187:drug effects*; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D009474:Neurons / Q000502:physiology*; D009479:Neuropeptides / Q000502:physiology*; D011450:Prostaglandin Endoperoxides, Synthetic / Q000037:antagonists & inhibitors / Q000633:toxicity; D011453:Prostaglandins / Q000502:physiology*; D051381:Rats; D011919:Rats, Inbred Strains; D013779:Tetrodotoxin / Q000494:pharmacology; D014661:Vasoconstriction / Q000502:physiology; D014664:Vasodilation / Q000502:physiology
D016861:Cyclooxygenase Inhibitors; D016232:Endothelins; D009479:Neuropeptides; D011450:Prostaglandin Endoperoxides, Synthetic; D011453:Prostaglandins; D013779:Tetrodotoxin; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D002211:Capsaicin; D007213:Indomethacin